Lisvy®
FC-Patch Low, Gestodene (GES) + Ethinyl Estradiol (EE) Patch
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Transdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Phase IV
- Developer(s)/researcher(s): WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Details
- API: Ethinyl Estradiol, Gestodene
- Target: Estrogen Receptor, Androgen Receptor, PAR1
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Regimen: 3 Weeks Applied/1 Week Removed
- MPT: Not Potential MPT
Product Status
Lisvy lost all market authorizations by Jan 2019, resulting in the termination of a study to evaluate safety
History
This patch was approved in the EU in 2014 and was licensed by Bayer to Gedeon Richter. Market entry occurred in late 2015, under the name Lisvy®. Gedeon Richter sponsored additional Phase IV evaluation. Product was withdrawn in October 2016 over concerns about the results of a stability test run by Bayer.